This review presents a new unified view of the pathogenesis of three common causes of acquired retinal degenerative disease—diabetic retinopathy, age related macular degeneration, and retinopathy of prematurity. In these three conditions, angiogenesis has a predominant role in the development of sight threatening pathology. Angiogenesis is controlled by among other factors the expression of vascular endothelial growth factor (VEGF), which in turn is regulated by absolute and relative lack of oxygen. The severe pathological manifestations of these three conditions are not part of a general underlying disease process because they are peculiar to the eye, and the profound hypoxia that develops in normal retina during dark adaptation (rod driven hypoxia) is an adequate and elegant additional factor to explain their pathogenesis. A large number of experimental reports support this conclusion, although rod driven anoxia is not generally considered as a causal factor in ocular disease. However, the hypothesis can be critically tested, and also suggests novel methods of treatment and prevention of these conditions that may be simpler and more inexpensive than current therapies and that have a smaller potential for adverse effects.

Three common blinding diseases—diabetic retinopathy (DR), retinopathy of prematurity (ROP) in oxygen treated neonates, and age related macular degeneration (ARMD)—are peculiar to the eye. The hallmark of these conditions is angiogenesis, the formation of new blood vessels, but the processes that give rise to them are apparently confined to the retina. Recent discoveries have detailed various mechanisms of angiogenesis in the eye, in particular the role of hypoxia induced vascular endothelial growth factor (VEGF), so it is now becoming meaningful to ask what local factors might account for the especial damage to the retina in DR, ROP, and ARMD. One feature that distinguishes the retina from other parts of the central nervous system and from other organs is the presence of large numbers of specialised photoreceptor cells—140 000 000 rods and 6 000 000 cones. We suggest that the special susceptibility of the retina is caused by two properties of photoreceptor cells—their signal transduction mechanism, found in no other neuron, is very energy demanding. In darkness the surface membrane of the rod outer segment is leaky, and water and sodium enter, to be extruded by pumps in the inner segment. Light seals the leaks in the outer segment, reduces or stops the dark current and promptly halts the pump action, reducing metabolism and oxygen uptake. The maximum magnitude of the dark current under strict dark adapted conditions indicates that the rod circulates its entire cytosol volume in 30 seconds, and this process produces more heat and consumes more oxygen than any function in any other cell. Although the

DIABETIC RETINOPATHY
Histopathology of the condition peculiar to the eye
Diabetes, experimental and clinical, selectively damages retinal microvessels. Elsewhere, the diabetic state causes thickening of capillary basement membrane, but only in retinal blood vessels is there loss of pericytes, and swelling and damage to capillary endothelial cells that result in the capillary dropout, microaneurysms, leakage, cellular damage, and new blood vessel growth that characterises DR. This indicates that local factors unique to the retina provoke DR, although retina is often considered “an approachable part of the brain.” The main difference between retina and brain tissue is, of course, the photoreceptors.

Energy requirements of photoreceptors
Their signal transduction mechanism, found in no other neuron, is very energy demanding. In darkness the surface membrane of the rod outer segment is leaky, and water and sodium enter, to be extruded by pumps in the inner segment. Light seals the leaks in the outer segment, reduces or stops the dark current and promptly halts the pump action, reducing metabolism and oxygen uptake. The maximum magnitude of the dark current under strict dark adapted conditions indicates that the rod circulates its entire cytosol volume in 30 seconds, and this process produces more heat and consumes more oxygen than any function in any other cell. Although the

Abbreviations: AGEs, advanced glycation end products; ARM, age related maculopathy; ARMD, age related macular degeneration; CNV, choroidal neovascularisation; DR, diabetic retinopathy; PRP, panretinal photocoagulation; ROP, retinopathy of prematurity; VEGF, vascular endothelial growth factor.
Rod driven hypoxia from a face mask. Therefore, even at stage 0, there must promptly, though only partially, reversed by inhaling oxygen. It has been shown that several of these losses can be protected and neuroprotective functions as well. Evidence is available for a role of VEGF-A and its receptors in this clinical stage is very well documented.1

Retinal anoxia in dark adaptation is present in normal eyes

Experiments with oxygen microelectrodes in normal eyes show a precipitous drop in partial oxygen pressure (pO2) as the microelectrode passes from the level of the choroidal blood vessels to fall in a minimum in the vicinity of the rod mitochondria and the photoreceptor cell synapses in the outer plexiform layer. In dark adapted eyes this minimum pO2 tension is zero, but even during a brief flash of light it reaches 30 mm Hg. Unlike other brain cells, rods can apparently function in such ultra low oxygen environments but their remarkably intense activity in darkness reduces the pO2 of the inner retina, a region served by blood vessels that penetrate inward from the vitreal surface but do not actually reach the rod cells. Therefore, when rods operate at maximum activity, a relative anoxia may develop in the inner portions of the retina in disease states with less than optimal oxygen supply.

Relative impairment of oxygen supply in early (grade 0 and 1) DR

Clinical DR appears to develop years after the condition is diagnosed. But during the preclinical period, although the fundus is normal (stage 0), psychophysical and electrophysiological experiments demonstrate that anomalies are developing, especially in rod vision (reviewed by Arden13). It has been shown that several of these losses can be promptly, though only partially, reversed by inhaling oxygen from a face mask. Therefore, even at stage 0, there must be a degree of oxygen lack in the retina of people with diabetes. Thus, the loss of dark adaptation in people with diabetes at stage 0 is explicable. Diabetes causes a series of slight changes in the circulation: glycosylated haemoglobin has a Michaelis-Menton curve shifted slightly to the right, basement membranes thicken, and red blood cell walls stiffen slightly, reducing ease of transport through the capillaries. In most tissues, these modifications would be of little consequence, but the retina has very little reserve capacity, and slight reductions in oxygen supply would tend to decrease the pO2. This cannot fall below the zero level found in the region of the rod mitochondria, but proximal and distal to this point pO2 will be reduced. This concept is supported by findings in diabetic cats, where retinal oxygen tension is reduced relative to normal, even in regions with no fluorescein angiographic evidence of actual capillary dropout.26

Production of cytokines in diabetic retina enhanced by hypoxia

Hyperglycaemia is the first signal to trigger the onset of DR and the cascade of metabolic and biochemical changes. High levels of intracellular glucose cause, among other changes, a state of “pseudohypoxia” in retinal cells. (Pseudo)hypoxia may upregulate factors such as vascular endothelial growth factor A (VEGF-A). VEGF is a prime regulator of angiogenesis and vascular permeability (reviewed by Ferrara25), but may have vasoprotective and neuroprotective functions as well. Evidence is available for a role of VEGF-A in the early stage of DR, as retinal VEGF expression by activated Müller cells is increased a few weeks after the onset of diabetes in rats. Intracellular pseudohypoxia, high levels of glucose and advanced glycation end products (AGEs) all induce increased VEGF expression in cells in vivo and in vitro.21-23 We suggest that in preclinical DR, the increased anoxia associated with complete dark adaptation is a crucial and necessary driving force of VEGF upregulation, in synergy with the consequences of chronic hyperglycaemia. Therefore, even in the preclinical phase of diabetic retinopathy, dark adapted rods are instrumental in the increase of VEGF expression. VEGF overexpression may reflect a stress response enabling survival of vascular and neuronal cells, but it also induces early blood-retinal barrier breakdown, leucocyte adhesion to retinal vessels, swelling of endothelial cells, and proliferation of endothelial cells.

Once this increase is established, repeated insults of endothelial apoptosis and reactive proliferation probably cause replicative senescence of endothelial cells resulting in the capillary dropout seen in clinical DR, which, by itself, may lead to a vicious circle of ischaemia, VEGF production, endothelial swelling and capillary non-perfusion, reinforcing the production of anoxia. This scheme of events can easily be envisaged against the background of rod induced anoxia acting as an independent driving force. Later, when clinical DR is established, and widespread vascular leakage, capillary dropout, and neovascularisation can be seen, the anoxia associated with DR is evident (see fig 1). The part played by VEGF-A and its receptors in this clinical stage is very well documented.

Evidence that DR is caused by local anoxia

Evidence is plentiful for the suggestion that “rod driven anoxia” triggers the changes that cause DR. As predicted, DR does not occur in patients who have diabetes and retinitis
pigmentosa, because rod outer segments are reduced in this condition. Proliferative DR may even regress in the presence of retinal degenerations such as retinitis pigmentosa. In the mitochondrial disorder MIDD 3243, which begins in adult life, diabetes is characteristic, and DR commonly occurs unless a retinal degeneration also develops. Some people with longstanding diabetes (types 1 and 2) develop no signs of DR at all. In a group of these, it has been shown that the upregulating effect of anoxia on blood white cell VEGF production is greatly reduced. However, the best evidence of the importance of anoxia is (i) the success of the common treatment of DR, panretinal photocoagulation, which was introduced to destroy retinal tissue thought to be liberating "toxins," but which may work simply by destroying enough rods to increase retinal pO2, and (ii) the recent report that breathing oxygen from nasal tubes for 3 months improves visual acuity and partially reverses the appearance of the macula in cases of diabetic maculopathy. Such treatment only provides <10% more oxygen to the retina. An alternative strategy, light adaptation during sleep, could reduce the oxygen requirement by ~50% and should therefore be at least as effective.

Other causes of DR, and predictions arising from the new hypothesis

Of course several systems contribute to diabetic retinopathy. The effects of glucose and insulin are well known, and the polyol pathway, and pseudohypoxia that is associated with NAD-NADH levels also can cause retinal damage. In experimental oxygen induced retinopathy, knockout of insulin receptors, which are indirectly necessary for VEGF activity, reduces vascularisation by 50%, but knockout of rods in mice prevents any vascular proliferation in this model. Almost the only time human rods ever dark adapt (and maximise their oxygen needs) in our electrically lit modern environment is during sleep. Our hypothesis predicts that if people with diabetes and grade 0–I retinopathy were to sleep in light levels of 1–10 cd/m², sufficient light would pass through the lids to protect against DR. (Consideration of the quantity of light required can be found in the paper by Arden et al.) Another testable prediction is that elderly people with diabetes who suffer from sleep apnoea would have considerably more DR than those who do not.

RETINOPATHY OF PREMATURITY

Rod driven anoxia is also the probable cause of ROP. In a well known mouse model of ROP, pups are placed in 75% oxygen from postnatal day P7 to P12. For the first two thirds of this period the eyelids are still closed, the rod outer segments have just begun to form, and the retina is growing and becoming vascularised. However, the hyperoxia results in an underdevelopment of retinal vasculature. Return to normal air at P12 coincides with the rapid development of rod outer segments, an increased retinal oxygen demand, and a large rise in retinal VEGF, so that by P17–21, a prominent proliferative retinopathy develops. However, if the same experiment is performed with mutant mice in which photoreceptor cells degenerate as their rod outer segments are differentiating, no proliferative retinopathy is found. Thus, in this model the activity or presence of rods is necessary for ROP to develop.

Despite great advances in paediatric care, ROP remains a relatively frequent complication of prematurity. It is customary to maintain premature infants in well illuminated intensive care units, though ordinary care units typically are maintained in reduced illumination. By analogy with the mouse experiments, our hypothesis suggests this is precisely the wrong arrangement. When neonates are maintained in a high oxygen environment, they should be exposed to as little light as possible to encourage growth of the retinal vessels. Red light (wavelength >660 nm) is scarcely absorbed by retinal rods; general and local illumination with red light emitting diodes should suffice for all necessary manipulations. When the neonate is returned to a normal air environment, the room should be brightly lit, so that the oxygen demand of the still immature eye is minimised. Brief trials would show whether this regime results in less ROP. Experimental evidence exists supporting our hypothesis. In the mouse model, ROP is less prominent in litters kept continuously in darkness than those kept variably in light. In a multicentre trial in neonates, gogles absorbing 97% of ambient illumination were fitted at random to half of the babies. In this trial, the investigators’ hypothesis that bright light is harmful in neonates could not be confirmed, as predicted by our hypothesis. That this trial did not show an opposite effect, consistent with our hypothesis, may be because of the amount of light passing through the gogles and the eyelids: with eyes open, retinal illumination was at photopic levels (4 cd/m²) behind the gogles. Because eyelids in neonates absorb less light than in adults, even with the lids closed, the retinal illumination in the “goggled” babies could have been sufficient for a light adapted state and have a protective effect against rod driven anoxia. In fact, the percentage of “goggled” babies who had ROP was slightly higher when the gogles were fitted early. Thus, the results of this clinical trial are at least consistent with our hypothesis.

AGE RELATED MACULAR DEGENERATION

Pathology

Age related maculopathy is a multifactorial condition. Though there is a genetic component, the rapidly increasing prevalence suggests the importance of environmental factors, and this is also indicated by histopathological studies (see below). The natural history shows that after the age of 55, increasing numbers of people develop large “soft” drusen, and the number of these increase with time. The drusen are seen in the posterior pole, often in a ring peripheral to the macula. The drusen are the clinically visible indicators of a collection of abnormal material between Bruch’s membrane and the retinal pigment epithelium (RPE) and Bruch’s membrane and the choroid, known as basal laminar and basal linear deposits, respectively. The RPE also becomes loaded with lipofuscin granules, resulting from phagocytosis and incomplete digestion of rod outer segment fragments. The volume of shed outer segments is ~2 μm³ per rod per day (see Young and Bok) and ~30 outer segments are phagocyted in each RPE cell. Analysis of the material contained in drusen shows it contains highly oxidised lipids, suggesting their formation by reactive oxygen species in senescent RPE cells that can no longer properly digest phagocyted rod outer segments. This failure leads to the accumulation of the deposits in both the “dry” and “wet” forms of ARMD. At the same time, abnormalities occur in the choroid. Thus, ARMD appears to be another disease whose manifestations are caused by local retinal factors. Visual function is affected early in the condition. Dark adaptation is slowed and less complete even in the early stages, and blue cone vision is also affected. Like DR, there is an asymptomatic “preclinical” stage but during this stage, drusen can be seen, pigment irregularities develop, and subtle losses of rod and cone function occur. The histologically verified loss of rods in the region of their highest density suggested that the condition is caused by the death of rods, but at a comparable stage there is also evidence of an obstructive barrier between choroid and RPE, which hinders the diffusion of oxygen from the choroid. Abnormal biochemical and immunocytochemical findings have been reported at this phase. With the loss of rods, irregularities and patchy diminution of choroidal...
blood flow may be seen in ageing eyes.46–47 The causal relations of these several findings are obscure. The primary disorder may be a defect in the RPE. Curcio48 raises the possibility that rod death leads to loss of a trophic factor necessary for normal cone function. However, in various other forms of night blindness, with absent or very reduced rod function, macular degeneration does not occur as an early event. The early stage (now often called age related maculopathy, ARM) occurs with little obvious symptomatology, but after some time, subjective visual disturbance occurs, associated with a change in retinal appearance. In the “dry” form, a limited retinal geographic atrophy eventually occurs. The fovea can be spared. In other cases, there is growth of new vessels from the choroid through Bruch’s membrane into the subretinal space, local oedema, and leakage (choroidal neovascularisation (CNV)). At this stage there is metamorphopsia, considerable reduction in acuity and obvious retinal damage. At such a stage the condition is often termed age related macular degeneration.

Cytokines in age related maculopathy
In development, and during adult life, the RPE controls the vascularity of the choroids.1 There is a normal strong polarisation of the secretion of VEGF basolaterally,44 and this paracrine relation with the choriocapillaris1 is disturbed by changes associated with ageing.61 In ageing, Bruch’s membrane thickens and becomes lipid laden,62 decreasing hydraulic conductivity and aqueous diffusion to the choroid.63 Even in the earliest stages of ARM, there may be retinal and RPE hypoxia because of the high metabolic requirements of the retina. Any diminution of VEGF secretion into the choroid will cause choriocapillaris atrophy, which indeed is observed in aged human eyes (reviewed by Witmer et al41), and reduce the oxygen supply to the adjacent RPE and retina. Thus ageing changes may enter a vicious circle, with alteration in RPE function eventually leading to further relative atrophy of choriocapillaris, the deposition of basal deposits, the relative impermeability of Bruch’s membrane, and documented loss of rod and cone function. At this clinical stage considerable retinal and RPE hypoxia upregulates VEGF, but transfer to the choriocapillaris is so reduced that a higher critical concentration may develop in the outer retina, or proximal to Bruch’s membrane, triggering choroidal neovascularisation.64–67 Alternatively, the anoxia can cause death of RPE and retina in geographic atrophy. Although many factors contribute to this sequence of change,68 critical participants are (i) abnormally metabolised material shed from the rods (responsible for the barrier to fluid transfer), and (ii) the extreme metabolic demands of rods (contributing heavily to anoxia and VEGF upregulation). This suggests that were rods to be absent the changes associated with ARM would develop more slowly.

Effects of lasering and panretinal photocoagulation on ARM
A small number of scattered laser burns in ARM reduces drusen, and can stabilise retinal function.77–88 The Choroidal Neovascularisation Prevention Trial (CNPT)89 also determined this, but the immediate high incidence of neovascularisation following their protocol led to termination of patient recruitment. However, after 5 years, the patients’ vision was not worse than controls, so that some retardation in development of ARM must have occurred. The longest small trial shows that the production of “wet” ARM is reduced 8 years after lasering. The mechanism whereby such light laserig removes drusen (at least temporarily), and apparently arrests the progress of retinal degeneration is not fully established. However, there is evidence that many more retinal burns, applied to people with much milder ARM, can have beneficial outcome. In people with type 2 diabetes ARM occurs at a similar frequency to normal controls.97 However, after panretinal photocoagulation (PRP) there is a marked reduction in the prevalence of wet and dry ARM99 and there is much anecdotal evidence to the same effect. All this suggests that an important factor in the development of ARM may be a relative anoxia in the outer part of the retina/RPE complex. The reported increase in cytokine formation86 is of course consistent with a local relative anoxia. The success of two differing anti-VEGF therapies100–105 in improving vision and fundus appearances in patients with ARM also indicates the importance of this cytokine in the development of the disease, and provides further indications of the importance of relative anoxia. Anoxia would necessarily be worse during periods of dark adaptation and, as in DR, it is possible that the condition would progress more slowly if such periods were avoided.

In summary, we propose that the huge numbers of peripheral rods are major driving factors in hypoxic retinopathies, and propose light adaptation during sleep, or early prophylactic inactivation or laser culling as a therapy.

ACKNOWLEDGEMENTS
Supported by the Edward en Marianne Blauw Fonds.

REFERENCES

www.bjophthalmol.com


